EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Dr Rahul Aggarwal provides context to the present post-hoc analysis of REDUCE-IT, which looked at the impact of TyG indices on CV risk and whether IPE was effective at reducing risk across baseline TyG tertiles. He then summarises the findings from the late breaking abstract that was presented at EASD and interprets the impact on future practice.
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid (EPA), including the latest sub-analysis of the REDUCE-IT trial, which analysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type 2 diabetes. For context, we reassess the role of diabetes in CV risk and the modifying effect of triglycerides in the diabetic population; we also consider the pleiotropic mechanisms that appear to make EPA an effective treatment in the diabetic state.
This programme is supported by an unrestricted educational grant from Amarin.
Educational Objective
- To provide an update and expert perspectives on recent clinical data from the REDUCE-IT trial, meta-analysis and systematic reviews on novel data with icosapent-ethyl.
Target Audience
- Cardiologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
Diabetes in CV Disease and the Role of Triglycerides
Prof Dirk Müller-Wieland considers the combined effects of diabetes and elevated triglycerides on CV events in primary and secondary prevention populations, the mechanisms that make triglyceride-lowering treatments like EPA effective on a background of diabetes and the current guideline recommendations on their use.
Part 2
Efficacy of Icosapent Ethyl Across the Spectrum of Baseline Triglyceride Glucose Indices
Dr Rahul Aggarwal provides context to the present post-hoc analysis of REDUCE-IT, which looked at the impact of TyG indices on CV risk and whether IPE was effective at reducing risk across baseline TyG tertiles. He then summarises the findings from the late breaking abstract that was presented at EASD and interprets the impact on future practice.
Faculty Biographies
Rahul Aggarwal
Physician and Cardiology Fellow
Dr Rahul Aggarwal is a Physician and Cardiology Fellow at Brigham and Women's Hospital, Harvard Medical School, Boston US.
With a medical degree from Boston University and residency at Beth Israel Deaconess, he is also an MBA candidate at MIT Sloan. His work focuses on advancing cardiovascular care through clinical trials, health policy, value-based care and large-scale data analytics.
Dr Aggarwal’s research has been featured in The New England Journal of Medicine, JAMA, Circulation, and The Lancet, with media coverage in The New York Times and NBC News. He develops risk prediction models and contributes to policy-shaping insights in cardiovascular health. He is also a peer reviewer for leading cardiology journals.